Evidence map›Paper›PMID 38394959›Full record

ArticleAddictive behaviors2024

Evidence for sex differences in the impact of cytochrome P450 genotypes on early subjective effects of cannabis.

Christal N Davis, John S Markowitz, Lindsay M Squeglia, Jarrod M Ellingson, Aimee L McRae-Clark, Kevin M Gray, Diana Kretschmer, Rachel L Tomko

Open access · greenAbstract read
In one paragraph

Article in Addictive behaviors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Christal N DavisRalph H. Johnson VA Medical Center, Charleston, SC, United States; Department of Psychiatry and Behavioral Services, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States; Mental Illness Research, Education and Clinical Center, Crescenz VA Medical Center, Philadelphia, PA 19104, United States; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address: Christal.Davis@va.gov.
John S MarkowitzCenter for Pharmacogenomics and Precision Medicine, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States.
Lindsay M SquegliaDepartment of Psychiatry and Behavioral Services, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.
Jarrod M EllingsonDepartment of Psychiatry, School of Medicine, University of Colorado, Aurora, CO 80045, United States.
Aimee L McRae-ClarkRalph H. Johnson VA Medical Center, Charleston, SC, United States; Department of Psychiatry and Behavioral Services, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.
Kevin M GrayDepartment of Psychiatry and Behavioral Services, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.
Diana KretschmerCenter for Pharmacogenomics and Precision Medicine, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States.
Rachel L TomkoDepartment of Psychiatry and Behavioral Services, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.
Medical University of South Carolina · USUniversity of Florida · USUniversity of Colorado Anschutz Medical Campus · US

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
MID-CAREER AWARD IN PATIENT-ORIENTED DRUG ABUSE RESEARCHK24DA038240 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MCRAE-CLARK, AIMEE L · 2014 to 2023
$1.9M
Mentoring Clinical Investigators in Patient-Oriented Adolescent Alcohol ResearchK24AA031052 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Lindsay Squeglia · 2024 to 2026
$644k
NCATS NIH HHS UL1 TR001450NIAAA NIH HHS K24 AA031052NIDA NIH HHS K24 DA038240
6 · The paper itself

Abstract

Early positive subjective effects of cannabis predict the development of cannabis use disorder (CUD). Genetic factors, such as the presence of cytochrome P450 genetic variants that are associated with reduced Δ9-tetrahydrocannabinol (THC) metabolism, may contribute to individual differences in subjective effects of cannabis. Young adults (N = 54) with CUD or a non-CUD substance use disorder (control) provided a blood sample for DNA analysis and self-reported their early (i.e., effects upon initial uses) and past-year positive and negative subjective cannabis effects. Participants were classified as slow metabolizers if they had at least one CYP2C9 or CYP3A4 allele associated with reduced activity. Though the CUD group and control group did not differ in terms of metabolizer status, slow metabolizer status was more prevalent among females in the CUD group than females in the control group. Slow metabolizers reported greater past year negative THC effects compared to normal metabolizers; however, slow metabolizer status did not predict early subjective cannabis effects (positive or negative) or past year positive effects. Post-hoc analyses suggested males who were slow metabolizers reported more negative early subjective effects of cannabis than female slow metabolizers. Other sex-by-genotype interactions were not significant. These initial findings suggest that genetic variation in CYP2C9 and CYP3A4 may have sex-specific associations with cannabis-related outcomes. Slow metabolizer genes may serve as a risk factor for CUD for females independent of subjective effects. Male slow metabolizers may instead be particularly susceptible to the negative subjective effects of cannabis.

Indexed as

CannabisMarijuana AbuseCytochrome P-450 CYP2C9Cytochrome P-450 CYP3AFemaleGenotypeHumansMaleSex CharacteristicsYoung AdultCytochrome P-450 CYP2C9Cytochrome P-450 CYP3ACannabis metabolismCannabis useCytochrome P450GeneticsSubjective effects

Identifiers

PMID38394959
PMCPMC10947802
OpenAlexW4392005224

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.